<DOC>
	<DOCNO>NCT00005064</DOCNO>
	<brief_summary>Phase I trial study effectiveness PS-341 treating patient refractory relapse acute myeloid leukemia , acute lymphoblastic leukemia , chronic myeloid leukemia blast phase , myelodysplastic syndrome . PS-341 may stop growth cancer cell block enzymes necessary cancer cell growth</brief_summary>
	<brief_title>PS-341 Treating Patients With Refractory Relapsed Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Chronic Myeloid Leukemia Blast Phase , Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose PS-341 patient refractory relapse acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome , chronic myeloid leukemia blast phase . II . Assess plasma pharmacology drug , ability inhibit proteasome function accelerate apoptosis circulate blast patient population . III . Assess antileukemic effect drug patient . OUTLINE : This dose-escalation study . Patients receive PS-341 IV bolus twice weekly 4 week follow 2 week rest . Treatment continue maximum 12 course absence unacceptable toxicity disease progression . Cohorts 2 patient receive escalate dos PS-341 maximum tolerate dose ( MTD ) determine . The MTD define dose level associate toxicity probability closest 0.2 30 patient treat .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>AML , ALL , highrisk MDS ( RAEB RAEBt ) : Not respond ( CR ) initial induction chemotherapy , Recurred initial CR &lt; 1 year , Recurred initial CR &gt; 1 year fail respond initial reinduction attempt , Recurred , OR Chronic myeloid leukemia myeloid blast phase Patients CML blast phase may receive PS341 first therapy blast phase fail treatment blast phase Patients refractory relapse acute promyelocytic leukemia eligible provide fail ATRAcontaining regimen Patients likely benefit allogeneic bone marrow transplantation ( i.e. , age &lt; 60 year physiological age histocompatible donor ) exclude study unless therapy feasible ECOG performance status = &lt; 52 ( Karnofsky &gt; = 50 % ) Total bilirubin &lt; 1.6 mg/ml ALT AST = &lt; 2.5 time institutional upper limit normal Creatinine &lt; 1.6 mg/ml creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Patients must chemotherapy 2 week prior enter study recover toxic effect therapy ; use hydroxyurea patient rapidly proliferative disease ( i.e. , absolute peripheral blood blast count &gt; = 5 x 10^9/L , increase &gt; = 1 x 10^9/L/24 hr ) allow 24 hour prior start therapy PS341 The effect PS341 develop human fetus recommend therapeutic dose unknown ; reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Because potential risk toxicity nursing infant secondary PS341 treatment mother unknown may harmful , breastfeed discontinue mother treated PS341 Ability understand willingness sign write informed consent document Patients undergoing therapy investigational agent Patients know brain metastasis CNS disease exclude clinical trail poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic toxicity Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia HIVpositive patient receive , antiretroviral thearpy ( HAART ) exclude study possible pharmacokinetic interaction ; appropriate study undertake patient receive , HAART therapy indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>